Diabetes Knowledge into Practice Podcast – Details, episodes & analysis

Join Prof. Francesco Giorgino and Dr. Darren McGuire as they discuss personalisation of treatment for patients with both type 2 diabetes and cardiovascular disease.

For more free education, go to ⁠⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠.

Faculty disclosures

Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Darren K. McGuire

Clinical trial leadership:

- Former: Esperion, AstraZeneca, CSL Behring

- Current: Novo Nordisk, Lilly USA, Pfizer, Boehringer Ingelheim, NewAmsterdam

Consultancy:

- Former: Merck & Co

- Current: Lilly USA, Boehringer Ingelheim, Novo Nordisk, Bayer, Lexicon, Altimmune, Esperion, Intercept Pharmaceuticals, Applied Therapeutics

Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Shehla Shaikh as they discuss strategies to help support type 2 diabetes patients during cultural events, such as observation of Ramadan.

For more free education, go to ⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠. Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Shehla Shaikh

Dr. Shaikh declares no current financial conflict of interest

Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

The past year has included the release of new guidelines on cardiovascular disease prevention and further data on cardioprotective agents in type 2 diabetes. In this episode we speak to Prof. Naveed Sattar about these guidelines and how best to help people with type 2 diabetes to reduce their cardiovascular risk.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Naveed Sattar declares the following financial relationships from the past 24 months: 

Advisory - Afimmune, Amgen, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi

Consulting - Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi

Speaker honoraria - Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi

Grant funding - AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Efpeglenatide for type 2 diabetes

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

This year saw the regulatory approval of the first dual GIP/GLP-1 dual agonist for type 2 diabetes. With several other multi-agonists in development, what does this mean for clinicians caring for people with type 2 diabetes?

Join Prof. Filip Knop for an overview of these new and emerging agents.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Filip Knop declares the following financial relationships from the past 24 months:

Honorarium recipient: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi

Speakers Bureau: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi

Consultant (Occasional): AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi

Advisor or Review Panel member: Eli Lilly, Novo Nordisk, Sanofi

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

The importance of weight loss in type 2 diabetes was a major topic at the recent American Diabetes Association (ADA) 2022 Scientific Sessions. As weight management is a complex issue affected by both genetic and environmental factors, we shed light on the latest advances in obesity care for individuals with type 2 diabetes.

Join us as we examine the effect of lifestyle interventions, metabolic surgery and the latest pharmaceutical agents, and discuss the state of the field with Dr Robert Kushner.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Dr Robert Kushner declares the following financial relationships from the past 24 months:

Consultant: Lilly, Pfizer

Board member: Novo Nordisk, WW

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

The ADA 2022 was full of interesting symposia, updates on ongoing clinical trials, and a draft of an updated ADA-EASD consensus report. This year’s conference also put particular emphasis on weight management in the setting of type 2 diabetes as well as its associated cardiovascular and kidney comorbidities.

Join us as we speak to Professor Jennifer Green about her conference highlights, including:

- Draft ADA-EASD Consensus Report

- Results from the SURMOUNT-1 clinical trial of tirzepatide in people with obesity

- Further data for dual and triple incretin agonists and their potential future role

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Jennifer Green declares the following financial relationships from the past 24 months:

Consultant: AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Hawthorne Effect/Omada (ended), Pfizer, NovoNordisk, Sanofi/Lexicon(ended), ICON/Vertex, and Anji.

Research support: Boehringer Ingelheim/Lilly, Merck, and Roche.

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

This is a special episode brought to you in association with Hepatology Knowledge into Practice.

NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future.

Join Professor Philip Newsome for an overview of current treatments in NASH, as well as how treatment may change in the future.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References:

References are available here

Disclosures:

Prof. Philip Newsome declares the following:

Consultant on behalf of the University of Birmingham: Boehringer Ingelheim, Novo Nordisk, Intercept, BMS, Gilead, Poxel Pharmaceuticals

Grants/Research Support recipient: Novo Nordisk, Boehringer Ingelheim

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

GLP-1 receptor agonists including semaglutide have been shown to offer benefits for glycemic control, weight loss and cardiovascular protection in type 2 diabetes. But where a patient requires more glycemic control, would a higher dose be of help?

The SUSTAIN FORTE trial was a randomized, double-blind, phase 3B trial that aimed to establish whether a higher dose of semaglutide was superior to the highest approved maintenance dose for glycemic control. Join Dr Juan Pablo Frias for a summary of the trial data and its potential implications for clinical practice.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

Reference:

Frías JP, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574.

Disclosures:

Dr Juan Pablo Frías declares the following:

Grants/Research Support, Advisory Boards, Honoraria receipt - Novo Nordisk, Eli Lilly, Sanofi, Pfizer

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding Information

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

In late 2020, we published an episode looking at the management of diabetes and heart failure when both present together. Since then, a wealth of evidence has been published on the effects of sodium glucose cotransporter type 2 (SGLT2) inhibitors in people with heart failure with or without type 2 diabetes. These findings have led to expanded indications for some of these agents to include heart failure. Today we will examine these data and their relevance in clinical practice in the setting of type 2 diabetes with heart failure. 

Joining us to discuss what these data mean for clinical practice is Prof. Javed Butler, who is Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Centre in Jackson, Mississippi. 

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. 

References available here

Disclosures:  

Prof. Javed Butler declares the following:

Consultant: Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharma,  Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sequana Medical, and Vifor 

Speakers Bureaus: Novartis, Boehringer Ingelheim-Lilly, Astra Zeneca, Janssen 

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. 

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. 

Funding: 

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

The 2022 Standards of Medical Care in Diabetes is published every year by the American Diabetes Association to reflect the latest available clinical evidence. The most significant updates this year include a lower age to begin screening for prediabetes and diabetes, an increased emphasis on individualization of treatment, and further recommendations around the use of technologies such as continuous glucose monitoring and treatment of obesity.

To hear more about some of these updates and their rationale, we’re joined by Professor Anne Peters, a member of the ADA’s Professional Practice Committee which reviews and updates the Standards.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Anne Peters disclosures are as follows:

Participation on an advisory board - Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Medscape, Novo Nordisk, ShouTi Inc, Vertex, Zealand

Research support - Abbott Diabetes Care, Dexcom, Insulet

Stock - Teladoc

Stock options - Omada Health

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.